Smart Immune secures funding from Bill & Melinda Gates Foundation
19 Apr 2023
Clinical StudyCell TherapyImmunotherapy
Preview
Source: Pharmaceutical Technology
Smart Immune’s SMART 101 will be assessed in a Phase I/II clinical trial to treat adult acute leukaemia patients. Credit: Animalculist / commons.wikimedia.org.
Preview
Source: Pharmaceutical Technology
Clinical-stage biotechnology company Smart Immune has secured $5m in equity investment from the Bill & Melinda Gates Foundation for expediting the development of its thymus-empowered ProTcell platform for the treatment of cancer and infectious diseases.
Smart Immune’s T-cell therapy platform, ProTcell is designed to ensure early immune reconstitution following allogeneic haematopoietic stem cell transplantation. It will also reverse thymic involution using its T-cell progenitor-based therapy.
When infused into a patient, T-cell progenitors move to the thymus and stimulate its activity,
The funding will help to advance a Phase I/II clinical trial of Smart Immune’s allogeneic cell therapy product SMART 101 in adult patients with acute leukaemia.
SMART 101 is produced from healthy donor-mobilised peripheral blood.
It will provide insights into the process by which the T-cell deficiency linked to human immunodeficiency virus (HIV) may be reversed.
Smart Immune believes that its SMART 101 can benefit a number of HIV patients, mainly in low and middle-income countries.
Smart Immune CEO and co-founder Karine Rossignol said: “We are delighted to be collaborating with the Gates Foundation to improve health outcomes for people around the world.
“Our work in re-arming patients’ immune systems is particularly exciting for global health since this concept has applications beyond oncology and into infectious diseases such as HIV.
“This investment from the Gates Foundation is an important milestone for Smart Immune.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free Whitepaper
Optimise your cell therapy process: a guide to cell thawing
Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.
This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
By Cytiva Thematic
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.